Smart ProTcell
Financiado
Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy...
Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patient’s own thymus in a record <3 months (vs. 15-24 months naturally), & reducing complications since infused in our 1st patient (June 2020). With strong IP, orphan drug label secured & traction across eminent KOLs in >7 countries, we face a window opportunity. With the EIC’s support, we pursue the less attractive-to-VC’s SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.
ver más
Duración del proyecto: 27 meses
Fecha Inicio: 2023-07-31
Fecha Fin: 2025-11-30
Fecha Fin: 2025-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
SMART IMMUNE
No se ha especificado una descripción o un objeto social para esta compañía.
